BACKGROUND The birth year-dependent onset of breast cancer (BC) in BRCA1/2 mutation carriers suggests a risk-modifying role for reproductive and life style factors. We therefore examined possible associations between these factors and age at diagnosis. METHODS Cox regression analysis and log-Rank testing were used to estimate the effect of potential life style factors on the onset of BC in 19...

BACKGROUND Germline mutations in the BRCA1 and BRCA2 genes are the most frequent known hereditary causes of familial breast cancer. Little is known about the interaction of age at diagnosis, estrogen receptor (ER) and progesterone receptor (PgR) expression and outcomes in patients with BRCA1 or BRCA2 mutations. METHODS A PubMed search identified publications exploring the association between ...

BACKGROUND It has become increasingly common to consider BRCA mutation status when determining optimal cancer risk management and treatment options in order to improve patient outcomes. Knowledge about the risk for hereditary cancer at or as close as possible to the time of diagnosis allows patients access to the most risk reduction options available. METHODS This paper illustrates the role o...

BACKGROUND Germline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and His...

The higher potential efficacy of alpha-particle radiopharmaceutical therapy lies in the 3- to 8-fold greater relative biological effectiveness (RBE) of alpha particles relative to photon or beta-particle radiation. This greater RBE, however, also applies to normal tissue, thereby reducing the potential advantage of high RBE. As alpha particles typically cause DNA double-strand breaks (DSB), tar...

Triple-negative is the rarest breast cancer biological subtype of cancer, but has most aggressive course. The resuls chemotherapy, especially in advanced disease, are unsatisfactory. Numerous clinical trials have been conducted, that resulted registrations new drugs decreasing risk recurrence and improving outcome patients with metastatic disease. article summarizes data on modern therapies reg...

OBJECTIVE To describe the population of women in southwestern Ontario who were diagnosed with potentially preventable BRCA mutation-related breast cancer. DESIGN Retrospective chart review. SETTING The Cancer Genetics Clinic of the London Regional Cancer Program in London, Ont. PARTICIPANTS Patients younger than 52 years of age who were referred to the London Regional Cancer Program Cance...